These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 2688329)

  • 1. Acute hypotensive reaction to etoposide with successful rechallenge: case report and review of the literature.
    Cersosimo RJ; Calarese P; Karp DD
    DICP; 1989 Nov; 23(11):876-7. PubMed ID: 2688329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful rechallenge with etoposide phosphate after an acute hypersensitivity reaction to etoposide.
    Bernstein BJ; Troner MB
    Pharmacotherapy; 1999 Aug; 19(8):989-91. PubMed ID: 10453971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute hypersensitivity reactions to etoposide in a VEPA regimen for Hodgkin's disease.
    Hudson MM; Weinstein HJ; Donaldson SS; Greenwald C; Kun L; Tarbell NJ; Humphrey WA; Rupp C; Marina NM; Wilimas J
    J Clin Oncol; 1993 Jun; 11(6):1080-4. PubMed ID: 8501494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypotension and cutaneous reactions associated with intravenous administration of etoposide in the dog.
    Ogilvie GK; Cockburn CA; Tranquilli WJ; Reschke RW; Weigel RM
    Am J Vet Res; 1988 Aug; 49(8):1367-70. PubMed ID: 2972235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Etoposide-induced hypersensitivity reactions. Report of two cases.
    Tucci E; Pirtoli L
    Chemioterapia; 1985 Dec; 4(6):460-2. PubMed ID: 3830414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypersensitivity to Etoposide in case of metastatic gestational choriocarcinoma.
    Lazović B; Milenković V; Delić M; Mazić S; Jeremic K; Hrgović Z
    Case Rep Oncol; 2013; 6(3):490-2. PubMed ID: 24163666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypersensitivity reactions to epipodophyllotoxins in children with acute lymphoblastic leukemia.
    Kellie SJ; Crist WM; Pui CH; Crone ME; Fairclough DL; Rodman JH; Rivera GK
    Cancer; 1991 Feb; 67(4):1070-5. PubMed ID: 1991254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two cases of suspected immunologic-based hypersensitivity reactions to etoposide therapy.
    Kasperek C; Black CD
    Ann Pharmacother; 1992 Oct; 26(10):1227-30. PubMed ID: 1421643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Etoposide desensitization. A case report].
    Alvarez Cardona A; Hernández Nieto L; Pérez Gómez M; Pedroza Meléndez A; Huerta López JG
    Rev Alerg Mex; 2010; 57(1):33-6. PubMed ID: 20857627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of anaphylactoid reactions to intravenous N-acetylcysteine.
    Bailey B; McGuigan MA
    Ann Emerg Med; 1998 Jun; 31(6):710-5. PubMed ID: 9624310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful treatment with etoposide phosphate in patients with previous etoposide hypersensitivity.
    Collier K; Schink C; Young AM; How K; Seckl M; Savage P
    J Oncol Pharm Pract; 2008 Mar; 14(1):51-5. PubMed ID: 18337441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I evaluation of a water-soluble etoposide prodrug, etoposide phosphate, given as a 5-minute infusion on days 1, 3, and 5 in patients with solid tumors.
    Budman DR; Igwemezie LN; Kaul S; Behr J; Lichtman S; Schulman P; Vinciguerra V; Allen SL; Kolitz J; Hock K
    J Clin Oncol; 1994 Sep; 12(9):1902-9. PubMed ID: 8083713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safe administration of etoposide phosphate after hypersensitivity reaction to intravenous etoposide.
    Siderov J; Prasad P; De Boer R; Desai J
    Br J Cancer; 2002 Jan; 86(1):12-3. PubMed ID: 11857004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infusion reactions are common after high-dose carmustine in BEAM chemotherapy and are not reduced by lengthening the time of administration.
    Perreault S; Baker J; Medoff E; Pratt K; Foss F; Isufi I; Seropian S; Cooper DL
    Support Care Cancer; 2017 Jan; 25(1):205-208. PubMed ID: 27614867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypersensitivity reactions to etoposide.
    Hoetelmans RM; Schornagel JH; ten Bokkel Huinink WW; Beijnen JH
    Ann Pharmacother; 1996 Apr; 30(4):367-71. PubMed ID: 8729891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safe administration of oral etoposide after hypersensitivity reaction to intravenous etoposide.
    Siderov J; Zalcberg J
    Anticancer Drugs; 1994 Oct; 5(5):602-3. PubMed ID: 7858295
    [No Abstract]   [Full Text] [Related]  

  • 17. Acute neurologic dysfunction after high-dose etoposide therapy for malignant glioma.
    Leff RS; Thompson JM; Daly MB; Johnson DB; Harden EA; Mercier RJ; Messerschmidt GL
    Cancer; 1988 Jul; 62(1):32-5. PubMed ID: 3289726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful rechallenge to etoposide after an acute vasomotor response.
    Tester WJ; Cohn JB; Fleekop PD; Rabinowitz MS; Lieberman JS
    J Clin Oncol; 1990 Sep; 8(9):1600-1. PubMed ID: 2391561
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase I trial of dacarbazine with cyclophosphamide, carmustine, etoposide, and autologous stem-cell transplantation in patients with lymphoma and multiple myeloma.
    Adkins DR; Salzman D; Boldt D; Kuhn J; Irvin R; Roodman GD; Lyons R; Smith L; Freytes CO; LeMaistre CF
    J Clin Oncol; 1994 Sep; 12(9):1890-901. PubMed ID: 7916039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Venous Flare Reactions: A Case Report of Reactions Following Etoposide Infusion.
    Mini Gill J; Frost J; Park R; Saria MG
    Clin J Oncol Nurs; 2018 Dec; 22(6):597-599. PubMed ID: 30452012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.